Myriad Genetics shares are trading higher after Goldman Sachs upgraded the stock from Sell to Buy and raised its price target from $18 to $25.
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs upgraded Myriad Genetics from Sell to Buy and raised its price target from $18 to $25, causing the stock to trade higher.
May 23, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics stock is trading higher after Goldman Sachs upgraded it from Sell to Buy and raised its price target from $18 to $25.
The upgrade from Goldman Sachs, a major financial institution, is a strong positive signal for Myriad Genetics. The increased price target indicates higher expected future performance, which is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100